Symplocamide A, a potent cytotoxin and chymotrypsin inhibitor from the marine Cyanobacterium Symploca sp

J Nat Prod. 2008 Jan;71(1):22-7. doi: 10.1021/np070280x. Epub 2007 Dec 29.

Abstract

Investigation of a Symploca sp. from Papua New Guinea has led to the isolation of symplocamide A (1), a potent cancer cell cytotoxin, which also inhibits serine proteases with a 200-fold greater inhibition of chymotrypsin over trypsin. The complete stereostructure of symplocamide A was determined by detailed NMR and MS analysis as well as chiral HPLC analysis of the component amino acid residues. The presence of several unusual structural features in symplocamide A provides new insights into the pharmacophore model for protease selectivity in this drug class and may underlie the potent cytotoxicity of this compound to H-460 lung cancer cells (IC50=40 nM) as well as neuro-2a neuroblastoma cells (IC50=29 nM).

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / isolation & purification*
  • Antineoplastic Agents / pharmacology*
  • Chymotrypsin / antagonists & inhibitors*
  • Cyanobacteria / chemistry*
  • Cytotoxins / chemistry
  • Cytotoxins / isolation & purification*
  • Cytotoxins / pharmacology*
  • Depsipeptides / chemistry
  • Depsipeptides / isolation & purification*
  • Depsipeptides / pharmacology*
  • Drug Screening Assays, Antitumor
  • Humans
  • Leishmania donovani / drug effects
  • Marine Toxins / chemistry
  • Marine Toxins / isolation & purification*
  • Marine Toxins / pharmacology*
  • Molecular Structure
  • Papua New Guinea
  • Plasmodium falciparum / drug effects
  • Trypanosoma cruzi / drug effects

Substances

  • Antineoplastic Agents
  • Cytotoxins
  • Depsipeptides
  • Marine Toxins
  • symplocamide A
  • Chymotrypsin